Butale Bakani, Woolley Ian, Cisera Kathryn, Korman Tony, Soldatos Georgia
Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Vic., Australia.
Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Vic., Australia; and Monash Infectious Diseases, Monash Health, Melbourne, Vic., Australia.
Sex Health. 2022 Dec;19(6):580-582. doi: 10.1071/SH22070.
Diabetes is an increasingly common co-morbidity in people living with HIV (PLWH). Given new evidence demonstrating cardiovascular benefits of sodium glucose transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1RA) in diabetic patients, we reviewed medical charts of 262 PLWH at Monash Health through a 1-year retrospective cohort study to determine the rates of their use. Prevalence of diabetes was 13.4% (35) and 60% (21) had microvascular and macrovascular complications. Only 4% (95% CI 0.1%-19.6%) of diabetic patients were receiving SGLT2i and 19% (95% CI 6%-39.4%) were receiving GLP1RA. Prescribers should carefully consider their choice of glucose-lowering medication when treating PLWH.
糖尿病在人类免疫缺陷病毒感染者（PLWH）中是一种日益常见的合并症。鉴于有新证据表明钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）和胰高血糖素样肽1受体激动剂（GLP1RA）对糖尿病患者有心血管益处，我们通过一项为期1年的回顾性队列研究，对莫纳什健康中心262名PLWH的病历进行了审查，以确定这些药物的使用比例。糖尿病患病率为13.4%（35例），60%（21例）有微血管和大血管并发症。仅4%（95%CI 0.1%-19.6%）的糖尿病患者正在接受SGLT2i治疗，19%（95%CI 6%-39.4%）正在接受GLP1RA治疗。在治疗PLWH时，处方者应仔细考虑其降糖药物的选择。
